SCHEMBL4314487

SCHEMBL4314487

COCCCNCCCOc1cc(NC(=O)c2sccc2C)c(C=Cc2n[nH]c3ccccc23)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 3/20 0.48
▸ AURKB Q96GD4 3/20 0.48
▸ KDM4E B2RXH2 3/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ RAB9A P51151 3/20 0.35
▸ NTRK1 P04629 1/20 0.35
▸ NTRK2 Q16620 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ FLT3 P36888 1/20 0.34
▸ FGFR1 P11362 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4314467 1.00 AURKA (0.48) AURKAAURKBKDM4ESMN1; SMN2MEN1
SCHEMBL4327238 0.90 AURKA (0.53) AURKAAURKBKDM4ESMN1; SMN2MEN1
SCHEMBL4327231 0.90 AURKA (0.53) AURKAAURKBKDM4ESMN1; SMN2MEN1
SCHEMBL4314475 0.90 AURKA (0.47) AURKAAURKBKDM4ESMN1; SMN2MEN1
SCHEMBL4314491 0.90 AURKA (0.47) AURKAAURKBKDM4ESMN1; SMN2MEN1
SCHEMBL4317389 0.89 AURKA (0.47) AURKAAURKBSMN1; SMN2NPC1RAB9A
SCHEMBL4317404 0.89 AURKA (0.47) AURKAAURKBSMN1; SMN2NPC1RAB9A
SCHEMBL4324776 0.86 AURKA (0.51) AURKAAURKBMAPTALDH1A1NTRK2
SCHEMBL4324783 0.86 AURKA (0.51) AURKAAURKBMAPTALDH1A1NTRK2
SCHEMBL4313384 0.85 AURKA (0.57) AURKAAURKBKDM4ESMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885KDM4E 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback